Publications by authors named "O A Alabas"
Importance: Biologics used for plaque psoriasis have been reported to be associated with an atopic dermatitis (AD) phenotype, or paradoxical eczema, in some patients. The risk factors for this are unknown.
Objective: To explore risk of paradoxical eczema by biologic class and identify factors associated with paradoxical eczema.
Article Synopsis
- The study investigates biologic therapy survival in patients with moderate-to-severe psoriasis, focusing on the impact of age at onset and HLA-C*06:02 status on treatment outcomes.
- Data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) and the Biomarkers and Stratification To Optimize outcomes in Psoriasis (BSTOP) were analyzed to assess treatment effectiveness and safety.
- Findings reveal differences in biologic survival rates related to the patient's age at psoriasis onset and their HLA-C*06:02 genetic status, leading to insights that may inform individualized treatment approaches.
Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment.
Objectives: To evaluate the incidence and risk factors of anti-TNFα treatment cessation owing to liver, blood and renal side-effects, and to estimate the cost-effectiveness of alternate intervals between monitoring blood tests.
Methods: A secondary care-based retrospective cohort study was performed.